Affordable Access

deepdyve-link
Publisher Website

Adding quantitative muscle MRI to the FSHD clinical trial toolbox.

Authors
  • Mul, Karlien1
  • Vincenten, Sanne C C2
  • Voermans, Nicol C2
  • Lemmers, Richard J L F2
  • van der Vliet, Patrick J2
  • van der Maarel, Silvère M2
  • Padberg, George W2
  • Horlings, Corinne G C2
  • van Engelen, Baziel G M2
  • 1 From the Department of Neurology (K.M., S.C.C.V., N.C.V., G.W.P., C.G.C.H., B.G.M.v.E.), Radboud University Medical Center, Nijmegen; and Department of Human Genetics (R.J.L.F.L., P.J.v.d.V., S.M.v.d.M.), Leiden University Medical Center, the Netherlands. [email protected] , (Netherlands)
  • 2 From the Department of Neurology (K.M., S.C.C.V., N.C.V., G.W.P., C.G.C.H., B.G.M.v.E.), Radboud University Medical Center, Nijmegen; and Department of Human Genetics (R.J.L.F.L., P.J.v.d.V., S.M.v.d.M.), Leiden University Medical Center, the Netherlands. , (Netherlands)
Type
Published Article
Journal
Neurology
Publisher
Ovid Technologies (Wolters Kluwer) - American Academy of Neurology
Publication Date
Nov 14, 2017
Volume
89
Issue
20
Pages
2057–2065
Identifiers
DOI: 10.1212/WNL.0000000000004647
PMID: 29030457
Source
Medline
License
Unknown

Abstract

We show a strong correlation between quantitative muscle MRI and clinical outcome measures. Muscle MRI is able to detect muscle pathology before clinical involvement of the leg muscles. This indicates that quantitative leg muscle MRI is a promising biomarker that captures disease severity and motor functioning and can thus be included in the FSHD trial toolbox.

Report this publication

Statistics

Seen <100 times